N/A
Completed N=20
Pharmacokinetics of Ceftazidime-avibactam Among Critically-ill Patients Receiving CVVHDF
Source: ClinicalTrials.gov NCT04358991 ↗Enrolled (actual)
20
Serious AEs
0.0%
Results posted
May 2020
Primary outcomePrimary: Serum Levels of Ceftazidime and Avibactam Among Critically-ill Patients — 80.6; 15.9 mcg/mL
Summary
Ceftazidime-avibactam is used for treatment of invasive Gram-negative bacterial infections among critically ill patients, including those on continuous venovenous hemodiafiltration . However, dosing of ceftazidime-avibactam for these patients remains undefined. The purpose of this study was to evaluate the pharmacokinetics of ceftazidime and avibactam among critically-ill patients, including those receiving CVVHD. This is a registration of Dr. Shields' exempt project under IRB approved research study STUDY19040363
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Serum Levels of Ceftazidime and Avibactam Among Critically-ill Patients |
80.6; 15.9 | — |
Eligibility Criteria
Inclusion Criteria
- Adult patients receiving ceftazidime-avibactam as standard care
Exclusion Criteria
- Less than 18 years-old
Data sourced from ClinicalTrials.gov (NCT04358991). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.